Anticholinergic Properties: Hydroxyzine vs Quetiapine (Seroquel)
No, hydroxyzine and quetiapine do not have the same anticholinergic properties—hydroxyzine has significantly stronger antimuscarinic effects than quetiapine, and critically, neither should be used as sleep aids given the evidence against both agents for insomnia treatment.
Key Pharmacologic Differences
Hydroxyzine (Antihistamine)
- Strong anticholinergic activity due to its antimuscarinic adverse effect profile 1
- The 2019 Beers Criteria carry a strong recommendation to avoid antihistamines in older adults specifically because of these antimuscarinic effects 1
- Tolerance to sedative effects develops after only 3-4 days of continuous use, limiting even short-term benefit 1
- Common anticholinergic side effects include dry mouth (14%), urinary retention risk, constipation, and cognitive impairment 2
Quetiapine (Seroquel)
- Moderate anticholinergic activity through its active metabolite norquetiapine, which has "moderate to strong affinity for several muscarinic receptor subtypes" 3
- Research quantifies quetiapine's anticholinergic activity at therapeutic doses as 0-5.4 pmol/mL atropine equivalents—substantially lower than clozapine (27-250) or olanzapine (1-15) 4
- FDA labeling specifically warns about anticholinergic effects including constipation (with risk of fatal intestinal obstruction), urinary retention, and cautions use with other anticholinergic medications 3
Critical Clinical Guidance: Neither Agent Recommended
The 2019 VA/DoD guidelines explicitly advise AGAINST both antihistamines and antipsychotics (including quetiapine) for chronic insomnia disorder 1. This is crucial context:
Why Hydroxyzine Should Not Be Used:
- Antimuscarinic adverse effects outweigh benefits 1
- Rapid tolerance development (3-4 days) 1
- Beers Criteria strong recommendation against use in elderly 1
Why Quetiapine Should Not Be Used:
- Sparse and unclear evidence with small sample sizes and short treatment durations 1
- Significant harms documented: increased mortality risk in elderly with dementia-related psychosis, increased suicidal tendencies in young adults 1
- Recent 2025 data shows low-dose quetiapine for insomnia in older adults increases risk of:
- Off-label use is widespread despite lack of confirmatory trials—79% of exploratory studies showing promise were never followed by large confirmatory trials 6
Comparative Anticholinergic Risk Profile
If forced to compare anticholinergic burden alone (though neither should be used):
- Hydroxyzine carries HIGHER anticholinergic risk with strong antimuscarinic effects that prompted Beers Criteria warnings
- Quetiapine carries MODERATE anticholinergic risk through norquetiapine, with quantifiable but lower activity than hydroxyzine
Both agents require caution with:
- Concurrent anticholinergic medications
- Urinary retention history
- Prostatic hypertrophy
- Constipation
- Elderly patients (cognitive impairment, falls risk)
Recommended Alternative Approach
The American Academy of Sleep Medicine (2017) and American College of Physicians guidelines recommend 7:
- First-line: Cognitive behavioral therapy for insomnia (CBT-I)
- Pharmacotherapy if needed: Short/intermediate-acting benzodiazepine receptor agonists or ramelteon as first-line agents
- Avoid: Antihistamines and antipsychotics due to lack of efficacy evidence and safety concerns
Common pitfall: Prescribing quetiapine at low doses (25-50mg) for insomnia because "it's just a small dose"—the 2025 data demonstrates significant harm even at low doses in older adults 5, and the evidence base remains inadequate across all age groups 6, 8.